@misc{cogprints4214,
          volume = {5},
          number = {2},
           month = {April},
          author = {Joydeep Ghosh and Johnson Francis and Barry J. Maron},
          editor = {Balbir Singh and Yash Lokhandwala and Johnson Francis and Anup Gupta},
           title = {Role of Implantable Cardioverter Defibrillators in the Treatment of Hypertrophic Cardiomyopathy

},
       publisher = {Indian Pacing and Electrophysiology Group},
            year = {2005},
         journal = {Indian Pacing and Electrophysiology Journal},
           pages = {72--75},
        keywords = {Hypertrophic cardiomyopathy; implantable defibrillator; sudden cardiac death
},
             url = {http://cogprints.org/4214/},
        abstract = {Hypertrophic cardiomyopathy (HCM) is an important cardiovascular disease with sudden cardiac death as the most devastating presentation. Implantable cardioverter defibrillators (ICD) are the optimal therapy for prevention of sudden death from ventricular tachycardia or fibrillation of any cause.  While there is no controversy with implanting ICDs in patients who have already survived a cardiac arrest, identifying high-risk patients for primary prevention in this disease remains a challenge. Implanting ICDs in patients with HCM is an important clinical consideration since many individuals could achieve normal or near-normal lifespans with this protection. 
}
}

<script src="//archive-bar.soton.ac.uk/archive-bar.js"></script>